Cytopharmaceuticals: An emerging paradigm for drug delivery
Cytopharmaceuticals: An emerging paradigm for drug delivery
复制标题
细胞药物：一种新兴的药物输送范例
DOI：
10.1016/j.jconrel.2020.08.063
复制
发表时间：
2020-12-10
影响因子：
10.8
通讯作者：
Zhang, Can
中科院分区：
文献类型：
--
作者：
Li, Weishuo;Su, Zhigui;Zhang, Can
细胞药物，其中药物/纳米药物离体加载到自体患者或同种异体供体来源的活细胞中/上，在改善的生物相容性、上级靶向和延长的循环方面显示出靶向药物递送的巨大前景。尽管在临床前研究中有某些令人印象深刻的治疗益处，但一些障碍阻碍了它们的临床应用，例如缺乏容易和方便的载体细胞获取方法，用于在不受干扰的载体细胞活力的情况下大规模制备细胞药物的技术，以及用于监测细胞药物的体内命运的模式。为全面了解细胞药物，促进其临床转化，本文综述了细胞药物的主要来源、细胞药物的制备技术、细胞药物（包括载体细胞和载药/纳米药物）在体内的命运以及细胞药物的应用前景。我们希望这篇综述能够阐明细胞药物制备的瓶颈，从而加速未来基于细胞的制剂的工业化。
Cytopharmaceuticals, in which drugs/nanomedicines are loaded into/onto autologous patient- or allogeneic donor-derived living cells ex vivo, have displayed great promise for targeted drug delivery in terms of improved biocompatibility, superior targeting, and prolonged circulation. Despite certain impressive therapeutic benefits in preclinical studies, several obstacles retard their clinical application, such as the lack of facile and convenient methods of carrier cell acquisition, technologies for preparing cytopharmaceuticals at scale with undisturbed carrier cell viability, and modalities for monitoring the in vivo fate of cytopharmaceuticals. To comprehensively understand cytopharmaceuticals and thereby accelerate their clinical translation, this review covers the main sources of various cytopharmaceuticals, technologies for preparing cytopharmaceuticals, the in vivo fate of cytopharmaceuticals including carrier cells and loaded drugs/nanomedicines, and the application prospects of cytopharmaceuticals. It is our hope that this review will elucidate the bottlenecks associated with cytopharmaceutical preparation, leading to the acceleration of future industrialization of cell-based formulations.